Title page for etd-0725114-101402


[Back to Results | New Search]

URN etd-0725114-101402
Author Bo-cheng Huang
Author's Email Address No Public.
Statistics This thesis had been viewed 5572 times. Download 0 times.
Department Institute of Biomedical Sciences
Year 2013
Semester 2
Degree Master
Type of Document
Language zh-TW.Big5 Chinese
Title To investigate the mechanism of protease-enhanced antibody activity to increase its therapeutic efficacy
Date of Defense 2014-07-24
Page Count 61
Keyword
  • Monoclonal antibody
  • specificity
  • Cancer
  • Autoimmune disease
  • Targeted therapy
  • Abstract Monoclonal antibody has become clinical medicine of a variety of disease widely. According to the statistics of drug use, monoclonal antibody therapies apply to cancer, autoimmune diseases, inflammation and many infectious diseases, etc. And through the market statistics point out the sales of monoclonal antibodies is up to $ 43 billion in the market of global antibody drug in 2010. Moreover single sales target several strains of antibodies will create more than $ 1 billion sales, including Colorectal cancer drug, ERBITUX® (Cetuximab)、breast cancer drug HERCEPTIN® (Trastuzumab)、rheumatoid arthritis drug REMICADE® (Infliximab) and HUMIRA® (Adalimumab) , etc. Over the past 20 years, monoclonal antibody therapy in cancer medicine has many successful examples, and become a staple of drugs in the medical profession base on the binding-specificity between antibody and antigen in order to block the cell pathway for inhibiting tumor growth or other disease. Monoclonal antibody therapy on medical breakthroughs and success promote many studies are still committed to finding out the diseases targeted therapy can be used as a sign of disease in order to benefit more patients, and more clinical treatment is combination of antibody with traditional chemotherapy drugs, radiation therapy, or other small molecule drugs for more effective inhibition of cancer cell proliferation to enhance the therapeutic efficacy. Thus the development of innovative monoclonal antibody has the full potential in future.
    Advisory Committee
  • Bing-hong Chen - chair
  • Ming-Hong Tai - co-chair
  • Tian-Lu Cheng - advisor
  • Files
  • etd-0725114-101402.pdf
  • Indicate in-campus at 99 year and off-campus access at 99 year.
    Date of Submission 2014-08-25

    [Back to Results | New Search]


    Browse | Search All Available ETDs

    If you have more questions or technical problems, please contact eThesys